{"product_id":"alxo-pestle-analysis","title":"(ALXO) ALX Oncology Holdings Inc. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis ALX Oncology Holdings Inc. PESTLE Analysis shows how political, economic, social, technological, legal, and environmental forces may impact the company and its strategy; the page includes a real preview\/sample so you can judge style and depth before buying. Purchase the full report to receive the complete, ready-to-use company-specific analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS-based, South San Francisco\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc. is based in South San Francisco, so U.S. federal and California policy directly affects its spending, hiring, and lab work. Clinical work depends on FDA review, and U.S. biotech rules can change trial start times, inspection timing, and compliance costs. In 2024, the FDA budget was about $7.2 billion, showing how heavily oversight shapes biotech execution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA-governed Phase 1b\/2 trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc.'s ALX148 is still in FDA-governed Phase 1b\/2 work, so U.S. review rules can shift enrollment, safety checks, and readout timing fast. That matters more in oncology combination studies, where small early cohorts often need protocol amendments after dose-limiting toxicities or endpoint changes, delaying the next data cut.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFederal cancer funding priorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFederal cancer funding sets the tone for ALX Oncology Holdings Inc.'s market. The National Cancer Institute got about $7.2 billion in FY2024, and that spend supports hematologic malignancy and solid tumor research that helps immuno-oncology trials move faster.\u003c\/p\u003e\n\u003cp\u003eWhen government budgets rise, pharma partners tend to back more programs; when they tighten, trial timing can slip. So shifts in NIH\/NCI funding can directly affect ALX Oncology Holdings Inc.'s partner interest and pipeline momentum.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDrug pricing policy pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eU.S. drug-pricing pressure stays a key risk for ALX Oncology Holdings Inc., because oncology payers and Medicare can reshape access and net pricing even after approval. The Inflation Reduction Act lets CMS negotiate prices for 10 Part D drugs in 2026, rising to 15 each year after, so specialty cancer drugs face more long-term reimbursement uncertainty. That makes early payer strategy just as important as clinical data.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCMS price talks can hit oncology access.\u003c\/li\u003e\n\u003cli\u003eNet price risk starts before approval.\u003c\/li\u003e\n\u003cli\u003eSpecialty cancer drugs draw extra scrutiny.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCross-border collaboration exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc. has 5 named cross-border partners: Merck, Zymeworks, Tallac Therapeutics, Selexis SA, and Crystal Bioscience. That spread ties its work to U.S., Swiss, and other policy regimes, so trade, export-control, and research-sharing rules can slow supply moves and joint development.\u003c\/p\u003e\n\u003cp\u003eFor a clinical-stage biotech, even one permit delay can hit timelines and cash use, since trial costs are fixed but filings move country by country.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e5 partners increase jurisdiction risk\u003c\/li\u003e\n\u003cli\u003eTrade rules can delay supply chains\u003c\/li\u003e\n\u003cli\u003eResearch rules can slow joint work\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALX Oncology Faces FDA, NIH, and Medicare Policy Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc. faces direct U.S. political risk from FDA review, NIH\/NCI funding, and Medicare pricing rules. The FDA’s FY2025 budget request was about $7.2 billion, while the National Cancer Institute’s FY2025 request was about $7.2 billion, so federal policy can move trial speed and partner appetite fast. The Inflation Reduction Act still raises long-term reimbursement pressure for oncology drugs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA FY2025 budget\u003c\/td\u003e\n\u003ctd\u003e$7.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNCI FY2025 request\u003c\/td\u003e\n\u003ctd\u003e$7.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare drug talks\u003c\/td\u003e\n\u003ctd\u003e10 Part D drugs in 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eMaps how political, economic, social, technological, environmental, and legal forces shape ALX Oncology Holdings Inc.'s risks, opportunities, and strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise ALX Oncology PESTLE snapshot that quickly highlights external risks and opportunities for faster decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources (clinical trials, SEC filings, industry reports) to speed due diligence and let investors verify ALX Oncology assumptions quickly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-stage, pre-revenue profile\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc. is still pre-revenue, so cash is the key economic driver; with no product sales, it relies on financing, grants, and partner support to fund trials. Clinical-stage biotech firms often burn through millions each quarter, so any delay in data readouts or approvals can force new equity raises and dilution. In 2025, the company still had 0 commercial revenue, which keeps funding risk high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D-intensive cost structure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALX Oncology’s R\u0026amp;D-heavy model is costly because oncology programs need long trials, GMP manufacturing, and FDA\/EMA work before any sales start. Its multiple Phase 1b\/2 studies across tumor types push spending up early, so cash burn stays high while product revenue is still absent. For a small biotech, tight budget control matters: every extra trial cohort can add months of runway pressure and raise dilution risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartnership-backed development model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc.'s partnership-backed model can split development costs with Merck and Zymeworks, easing the need to fund every trial alone. In high-burn biotech, that matters because late-stage oncology studies can run into tens of millions of dollars. External partners also signal scientific credibility, which can improve capital efficiency and lower financing pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiotech financing sensitivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc.’s financing access stays sensitive to rates, risk appetite, and biotech sentiment; when public markets are weak, small clinical-stage names often lose value fast after trial reads. In 2025, the Fed kept rates in a restrictive range, so equity raises stayed costly and partnership capital stayed selective. That makes each data readout a funding event, not just a clinical one.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRates shape dilution risk.\u003c\/li\u003e\n\u003cli\u003eTrial data can reset valuation.\u003c\/li\u003e\n\u003cli\u003ePartner capital is more selective.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialty oncology market potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eALX148 sits in oncology niches with strong pricing power because it targets hematologic malignancies and HER2-expressing solid tumors, where unmet need is still high. WHO says global cancer cases could reach 35 million a year by 2050, and HER2-positive breast cancer accounts for about 15% to 20% of cases, so late-stage success could support premium reimbursement and revenue growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh unmet need supports premium pricing.\u003c\/li\u003e\n\u003cli\u003eHER2 tumors broaden the addressable market.\u003c\/li\u003e\n\u003cli\u003eValue depends on late-stage approval.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALX Oncology’s 2025 Outlook Hinges on Cash, Trials, and Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc. has no product revenue in 2025, so its economic outlook still depends on cash runway, equity access, and partner funding. R\u0026amp;D spending stays high because oncology trials, GMP supply, and regulatory work cost millions before any sales start. Trial delays can force dilution, while a strong readout can quickly reset valuation. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eEconomic factor\u003c\/th\u003e\n\u003cth\u003e2025 impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e0 commercial revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFunding\u003c\/td\u003e\n\u003ctd\u003eEquity, grants, partners\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost base\u003c\/td\u003e\n\u003ctd\u003eHigh R\u0026amp;D burn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket risk\u003c\/td\u003e\n\u003ctd\u003eRates raise dilution risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eALX Oncology Holdings Inc. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact ALX Oncology Holdings Inc. PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic or investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh global cancer burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCancer kept a huge global burden in 2022, with 20 million new cases and 9.7 million deaths, and cases may reach 35 million by 2050. ALX Oncology Holdings Inc. targets blood cancers and solid tumors, where unmet need stays high and current options are often weak. That keeps demand for new therapies strong, especially in hard-to-treat disease areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAging patient population\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCancer risk rises sharply with age, and about 60% of U.S. cancer diagnoses and 69% of cancer deaths occur in people 65 and older. That expanding older patient pool supports steady demand for ALX Oncology Holdings Inc. oncology innovation. It also increases demand for therapies that can pair with standard-of-care regimens, since older patients often need combination treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeed for better tolerated treatments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients and clinicians increasingly prefer cancer therapies that work without heavy toxicity, and that matters for ALX Oncology Holdings Inc. as ALX148 is being tested in combinations where safety is critical. Globally, cancer caused about 9.7 million deaths in 2022, so demand for better-tolerated options stays high. That social pressure supports interest in newer immuno-oncology drugs that aim to add benefit without adding much burden.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTrial enrollment and diversity expectations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc. must recruit patients across tumor types and lines of therapy, but sponsors also face pressure to make trials more representative. In FDA reporting, Black patients were 8% of U.S. oncology trial participants vs about 13.6% of the U.S. population, so site choice and outreach now matter as much as protocol design. That can slow enrollment and raise execution cost.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDiverse enrollment is now a trial quality test.\u003c\/li\u003e\n\u003cli\u003eSite selection can make or break timelines.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatient trust in cancer innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmuno-oncology stays highly visible because cancer is still a huge public issue: GLOBOCAN 2022 estimated 20.0 million new cases and 9.7 million deaths worldwide, so patients watch new treatments closely. That awareness can speed interest in CD47 blockade, but trust rises only when ALX Oncology Holdings Inc. shows clear benefit and safety in data.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh awareness can lift trial interest.\u003c\/li\u003e\n\u003cli\u003eSafety data drives patient trust.\u003c\/li\u003e\n\u003cli\u003eClear efficacy beats hype.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAging Cancer Demand Supports ALX Oncology, But Trial Diversity Matters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc. depends on cancer care demand, and aging populations keep that need high: about 60% of U.S. diagnoses and 69% of deaths occur in people 65+. Social pressure also favors safer, better-tolerated drugs, so benefit-risk data matters.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal cancer load\u003c\/td\u003e\n\u003ctd\u003e20.0M cases, 9.7M deaths\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOlder patients\u003c\/td\u003e\n\u003ctd\u003e65+ drives most U.S. burden\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial diversity\u003c\/td\u003e\n\u003ctd\u003eEnrollment gaps can slow studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eDiverse trial enrollment and public trust can affect ALX Oncology Holdings Inc. timelines, costs, and adoption.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALX148 CD47-blocking platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALX148, now called evorpacept, is ALX Oncology Holdings Inc.'s lead asset and blocks CD47, the cancer cell signal that helps tumors hide from innate immune attack. \u003c\/p\u003e\n\u003cp\u003eThis platform matters because it targets a core cancer biology pathway, so it can support combo use across solid and blood cancers. \u003c\/p\u003e\n\u003cp\u003eIt is the main value driver in ALX Oncology Holdings Inc.'s pipeline, and its tech edge will be judged by whether later-stage data can show stronger efficacy and tolerability than earlier CD47 rivals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase 1b\/2 combination studies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc. is testing ALX148 in Phase 1b\/2 combination studies with pembrolizumab, with or without chemotherapy, and with zanidatamab. These multi-drug programs are technically hard because the company must show both safety and anti-tumor synergy at the same time. That raises the bar for translational and clinical data, since small dose or schedule changes can shift outcomes fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALTA-002 preclinical program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALTA-002 is ALX Oncology Holdings Inc.’s preclinical SIRPa TRAAC, aimed at activating both innate and adaptive immunity against cancer. As a preclinical asset, it adds a second platform beyond ALX148 and widens the company’s tech base.\u003c\/p\u003e\n\u003cp\u003eThat matters because ALX148 is still the core clinical program, so ALTA-002 gives ALX Oncology Holdings Inc. a deeper pipeline and more shots on goal before human data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiologics engineering partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc. depends on biologics engineering partners like Selexis SA and Crystal Bioscience to support cell-line design and antibody workflow execution. In biotech, that matters because manufacturability and platform quality can decide whether a program moves from research to clinic; ALX Oncology’s reported cash and cash equivalents were about $180 million at year-end 2024, so partner efficiency helps stretch capital.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupports cell-line development\u003c\/li\u003e\n\u003cli\u003eHelps antibody workflow speed\u003c\/li\u003e\n\u003cli\u003eImproves manufacturability odds\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNetworked innovation model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc. uses a networked innovation model, with Merck, Zymeworks, and Tallac Therapeutics widening its technical reach. Shared work gives ALX Oncology Holdings Inc. access to extra assets and specialist know-how, which matters as combo logic and biomarker selection keep shifting in oncology.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eAccess to partner platforms\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eShared development lowers build time\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eHelps test new combo strategies\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALX Oncology’s Evorpacept Must Prove Safer, Stronger Combo Results\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTechnological risk at ALX Oncology Holdings Inc. centers on whether evorpacept can prove cleaner, stronger combo efficacy than earlier CD47 drugs while staying safe across dosing partners. Its 2024 cash was about $180 million, so technical progress has to come fast enough to justify platform spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead asset\u003c\/td\u003e\n\u003ctd\u003eevorpacept\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, year-end 2024\u003c\/td\u003e\n\u003ctd\u003eabout $180 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey tech risk\u003c\/td\u003e\n\u003ctd\u003eCombo safety and synergy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA clinical trial compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a clinical-stage biotech with 0 approved products, ALX Oncology Holdings Inc. must keep every human study aligned with FDA rules on safety reporting, protocol adherence, and inspection readiness. FDA can inspect trial sites and sponsors before a BLA or NDA can move ahead, so even small deviations can slow approval. For ALX Oncology, compliance is not optional; it is the gate to any future revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGCP and ethics oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALX Oncology’s oncology trials must clear institutional review board review and follow good clinical practice, which is the core legal test for valid human studies. Because cancer patients can be highly vulnerable, informed consent and close safety monitoring matter as much as efficacy data. Any breach can weaken trial validity and raise reputational risk fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent and licensing protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc. depends on patents and licenses to protect its lead asset evorpacept and its preclinical pipeline. Its filings show 2 named licensing ties, with Selexis SA and Crystal Bioscience, which points to a structured IP base. In oncology, where each extra year of exclusivity can shape a drug’s multibillion-dollar value, patent coverage is a key legal shield.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eContracted collaboration obligations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc. is bound by joint programs with Merck, Zymeworks, and Tallac Therapeutics, so its legal risk sits in contract execution, data rights, and who owns development and commercialization decisions. Any breach or delay can trigger dispute costs, shut off partner data, or weaken IP control. One missed obligation can change the whole program.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003e3 active partner ties: Merck, Zymeworks, Tallac.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eContracts define data, work, and sales rights.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eDisputes can hit IP and cash flow fast.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHealthcare data privacy duties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc. must protect sensitive trial records, including patient histories, lab data, and consent files, because U.S. privacy rules like HIPAA govern how that data is collected, stored, and shared. Cross-partner studies with CROs, hospitals, and labs raise the risk of unauthorized access, so secure governance and audit trails matter. HHS OCR can impose multimillion-dollar HIPAA penalties, making documentation a real compliance cost.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHIPAA controls trial data use.\u003c\/li\u003e\n\u003cli\u003ePartner sharing needs tight contracts.\u003c\/li\u003e\n\u003cli\u003eAudit logs help prove compliance.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALX Oncology: Compliance and IP Terms Drive Value\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegally, ALX Oncology Holdings Inc. faces tight FDA, IRB, and GCP rules because it has 0 approved products and relies on human trials for value creation. Its IP base includes 2 named licensing ties and 3 active partner ties, so contract terms, data rights, and patent scope can move program control and future revenue fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal factor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA\/GCP compliance\u003c\/td\u003e\n\u003ctd\u003e0 approved products\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP and licensing\u003c\/td\u003e\n\u003ctd\u003e2 named licenses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner contracts\u003c\/td\u003e\n\u003ctd\u003e3 active partner ties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLab and biologics waste\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALX Oncology’s lab work creates chemical and biohazard waste that must follow EPA and state rules, so disposal is a fixed R\u0026amp;D cost. In U.S. biotech labs, regulated waste handling can add 5% to 15% to lab services spend, and noncompliance can trigger six-figure cleanup costs. That makes waste segregation, vendor control, and documentation part of routine operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing footprint management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc. is still clinical-stage, so its manufacturing footprint is mainly pilot batches and CDMO work, not full commercial output. Even at this scale, biologics programs use energy, water, cold storage, and single-use materials, so process design still affects emissions and waste. Cleaner batch yields and tighter supply planning can cut environmental intensity before launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClimate-related supply chain risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc. depends on third-party labs, shippers, and specialized research inputs, so weather delays or port and road disruption can slow materials and trial work.\u003c\/p\u003e\n\u003cp\u003eThat risk is real in California: the 2024 Park Fire burned more than 429,000 acres, showing how wildfire can strain transport, power, and local operations.\u003c\/p\u003e\n\u003cp\u003eBay Area firms also face grid and infrastructure outages, so even short regional emergencies can push trial timelines and raise costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eESG expectations in biotech\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eESG expectations are now material in biotech: the global health care sector is estimated to generate 4.4% of net greenhouse-gas emissions, so investors and partners look closely at energy use, lab waste, and supplier standards. For ALX Oncology Holdings Inc., that means vendor choice and waste handling can affect operating risk and deal terms. Strong ESG disclosure can also support reputation and financing access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4.4% of global emissions come from health care.\u003c\/li\u003e\n\u003cli\u003eEnergy and waste controls affect partner due diligence.\u003c\/li\u003e\n\u003cli\u003eESG scores can shape capital access and trust.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLimited direct emissions profile\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc. is a clinical-stage biopharma company, so its direct environmental footprint is usually far smaller than a drug maker’s. In its 2025 filing, it did not report material direct emissions figures, which points to low in-house Scope 1 and 2 exposure. Most impact sits in offices, labs, and outsourced research, so vendor oversight still matters.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow direct emissions risk\u003c\/li\u003e\n\u003cli\u003eLabs and offices drive footprint\u003c\/li\u003e\n\u003cli\u003eSupplier controls still matter\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat means ALX Oncology’s main environmental issue is not factory smoke, but how well it tracks emissions and waste across partners. Even with a small internal base, outsourced CRO and lab work can expand Scope 3 impacts fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALX Oncology’s Biggest Climate Risks Sit in Labs, Vendors, and Logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc.’s main environmental load is in labs and outsourced research, not large-scale manufacturing. Its 2025 filing did not show material direct emissions, but waste handling, cold storage, and shipped trial materials still create Scope 3 and disruption risk. Clean lab design and vendor controls matter most.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect emissions\u003c\/td\u003e\n\u003ctd\u003eNo material 2025 figure reported\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExposure\u003c\/td\u003e\n\u003ctd\u003eLabs, offices, CDMOs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMain risk\u003c\/td\u003e\n\u003ctd\u003eWaste and logistics disruption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57233981407497,"sku":"alxo-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/alxo-pestle-analysis.webp?v=1785710506","url":"https:\/\/dcfanalyst.com\/products\/alxo-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}